Image
|
Figure Caption
Fig. 5 Coumestrol reduces phosphorylated (p)-tau levels in cells co-expressing DYRK1A and tau. (A) As indicated, COS-7 and (B) HEK293 cells were cotransfected with EGFP-Tau441, pDsRed-DYRK1A, or both. Cells were treated with coumestrol at the indicated concentrations. Detection of DYRK1A-dependent tau phosphorylation using phospho-specific antibodies to indicated sites. Quantifying band intensities in COS-7 and HEK293 cells showed a dose-dependent reduction of cellular tau phosphorylation after coumestrol treatment.
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Reprinted from International journal of biological macromolecules, 282(Pt 4), Peng, C.H., Hwang, T.L., Hung, S.C., Tu, H.J., Tseng, Y.T., Lin, T.E., Lee, C.C., Tseng, Y.C., Ko, C.Y., Yen, S.C., Hsu, K.C., Pan, S.L., HuangFu, W.C., Identification, biological evaluation, and crystallographic analysis of coumestrol as a novel dual-specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor, 136860, Copyright (2024) with permission from Elsevier. Full text @ Int. J. Biol. Macromol.